AVLN 8-K 2026-07-01

Avalyn Pharma Inc. (AVLN) 8-K dated 2026-07-01 — accession 0001193125-26-292834.

Avalyn Pharma Inc. (AVLN) common stock.

Avalyn Pharma Inc. filed a 8-K on 2026-07-01. Accession 0001193125-26-292834.

This 8-K covers: Material agreement (Item 1.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported AVLN revenue for 2026-06-30 was $2.7M. Net income was -$28.9M. AVLN currently screens at market cap $1.40B.

Not investment advice. The AVLN SEC hub lists recent forms. The stock page is the research view.